Episode 184: PREMIUM – Two more blood pressure/chlolesterol changing drugs that are a flop
In episode 184, James and Mike don their PREMIUM critical appraisal hats yet again to report the results of important recent studies that examine the impact two “new” drugs, aliskiren and dalcetrapib, have on clinically important outcomes. Unfortunately, these well-designed studies show yet again there is no guarantee that if you change cholesterol or blood pressure that clinically important outcomes will decrease.
Show notes
1) Aliskiren
N Engl J Med 2012. DOI: 10.1056/NEJMoa1208799
2) Dalcetrapib
N Engl J Med 2012. DOI: 10.1056/NEJMoa1206797
Listening to this episode is for premium podcast members only. If you already have a membership, login to your account. If you aren't yet a premium subscriber, sign up today!
